Dr. Reddy’s Laboratories Limited (Dr. Reddy’s) is a global pharmaceutical company with proven research capabilities. The Company produces active pharmaceutical ingredients (APIs) and intermediates, and finished dosage forms and biologics products, and markets them globally, with a focus on India, the United States, Europe and Russia. The Company is vertically integrated and uses its active pharmaceutical ingredients and intermediates in its own finished dosage products. Dr. Reddy’s Laboratories Limited conducts basic research in the areas of cancer, diabetes, metabolic disorders, cardiovascular disease, inflammation and bacterial infection. The Company operates through five segments: formulations, active pharmaceutical ingredients and intermediates, generics, custom pharmaceutical services (CPS) and drug discovery. In September 2008, the Company announced the launch of Promius Pharma, its wholly owned subsidiary.
Axcan Pharma is a privately-held, leading specialty pharmaceutical company that develops and markets a wide range of products to treat gastrointestinal diseases and disorders, such as inflammatory bowel disease, cholestatic liver diseases, irritable bowel syndrome, and complications related to pancreatic insufficiency. All Axcan's activities underscore the Company's single, well-defined Mission - to improve the quality of care and health of patients suffering from gastrointestinal diseases and disorders by providing effective therapies for patients and their specialized caregivers. Through internal product development and synergistic acquisitions of products and companies, Axcan has built a leadership position in the North American gastroenterology market; just under 85 percent of the Company's business is generated from North American sales. Since Axcan markets its specialized products to a relatively cohesive community of physicians, its sales forces are able to reach this market more easily than pharmaceutical companies with a product portfolio targeting a more diverse range of diseases. Axcan's products are marketed by its own dedicated and specialized sales forces both in North America and the European Union. Axcan Pharma and its global operations are working hand-in-hand to become a multinational leader for disorders linked to gastroenterology. Currently, the Company markets more than 40 products and dosage strengths worldwide in the field of gastroenterology, including several that hold a leading market position. In addition to its marketing activities, Axcan carries out research and development of products at an advanced stage of development that it acquires or licenses from third parties. By combining its marketing expertise with its research and development experience, Axcan distinguishes itself from specialty pharmaceutical companies that focus solely on the distribution of products and offers potential licensors the prospect of rapidly expanding the market for their products. Axcan's unique expertise in its field, combined with its excellent industry reputation and international reach, has enabled the Company to maintain its consistent growth trend and attain its strong market position. Axcan's solid and stable base business provides a platform for the Company to capitalize on its proven business strategy, in order to continue to achieve significant future growth. The Company plans to continue to grow its business by: increasing market penetration and sales of existing products; developing and obtaining marketing approval for new products; in-licensing products and acquiring new products or companies; development of its research and development portfolio, and expanding geographically. Axcan's corporate headquarters are based outside of Montreal, Quebec, Canada. The Company employs almost 500 people worldwide and has additional offices in both the United States and France.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory